Topic: Incyte Corporation
CHICAGO (Reuters) - A second pivotal trial of ruxolitinib, developed by Incyte Corp and Novartis, met its goal of showing that the drug significantly reduces spleen size in myelofibrosis patients.The rare, but potentially deadly, blood cancer is characterized by bone marrow failure, ...
Myelofibrosis is a cancer characterized by bone marrow failure, enlarged spleen, poor quality of life and shortened survival Phase I/II data show Incyte's JAK1 and JAK2 inhibitor INCB18424 demonstrates durable clinical benefits including reduction of spleen size and alleviation of debilitating constitutional ...
Life-threatening bone marrow malignancy has no approved therapy. "The problem with myelofibrosis is the lack of available therapies for patients - there are none approved for this disease today," said principal investigator Srdan Verstovsek, M.D., Ph.D., associate professor in MD Anderson's Department ...
Incyte Corporation (INCY) Q2 2009 Earnings Call Transcript July 30, 2009 8:30 am ET. On the call are Paul Friedman, Incyte's President and Chief Executive Officer; Dave Hastings, Executive Vice President and Chief Financial Officer; and Rich Levy, Executive Vice President and ...
INCY) will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.. Srdan Verstovsek, M.D., Ph.D., Associate Professor, ...
From Around the Web
Video Gallery
-
Stock Trading Winner In Incyte Corporation ...
www.guerillastocktrading.com (CLICK HERE FOR THE FULL REPORT AND ...2010-12-23 -
Incyte CFFO Turns Negative- Global Financial ...
Cash Flow from Operations for Incyte Corporation for its twelve ...2012-02-04 -
INCY, MCP, PCS, ZSL - Stock Charts ...
05/03/11 - Yesterday we showed you the Boxer Shorts ...2011-05-04
